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We report a rare case of a laparoscopic splenectomy performed for a carcinoid metastasis. The patient represented with pleuritic
left-sided chest pain from pleural deposits 9 years following resection of a primary lung carcinoid tumour. They were found to
have a 4.7cm splenic lesion on CT with a probable left acetabular metastasis demonstrated on Gallium PET scan. The patient
underwent laparoscopic splenectomy fordebulking treatment of the splenic lesion that was conﬁrmed to be a splenic metastasisof
the resected carcinoid lung tumour. Followingan uncomplicated recovery, the patient was discharged on the second postoperative
day. On discharge, she received adjuvant therapy with Lutetium 177 DOTATATE. This is the ﬁrst report of a carcinoid splenic
metastasis successfully treated with laparoscopic splenectomy.
1.Introduction
The spleen is a rare location of metastasis from solid
tumours. In a recent review of 6,137 patients with metastatic
malignant tumours, only 59 (0.96%) involved the spleen.
In an earlier series of lung cancer patients, just 12 of 997
consecutive cases had splenic involvement. However, all 12
had other abdominal organ involvement in addition to the
spleen at the time of presentation [1]. Carcinoid metastasis
involving thespleen is extremely rare with only a few isolated
cases being reported to date. Falk and Stutte and Eriguchi
et al. report intraperitoneal spread of carcinoid tumours
from ileal and gastric primaries, respectively, whilst Takada
and Takami report on a case of isolated splenic metastasis
of a primary lung carcinoid treated with traditional open
splenectomy [2–4]. Due to the rarity of splenic metastasis,
optimal management must be determined on an individual
basis. In this case, the splenic metastasis of a primary
lung carcinoid was successfully treated with laparoscopic
splenectomy.Laparoscopicsplenectomy isnowconsideredto
be the gold standard for treatment of benign haematological
disease, with reduced morbidity and mortality compared to
open procedures. However, evidence for its use in malignant
disease of the spleen remains limited [5].
This case serves as a report of a rare event of metastatic
bronchial carcinoid involving the spleen and its successful
management with laparoscopic splenectomy.
2.Case Report
A 51-year-old lady was admitted to our hospital in February
2009 with left-sided pleuritic chest pain. She had a history
of left upper lobectomy in December 2000 for a primary
carcinoid tumour of the lung (chromogranin positive; no
mitotic activity; Ki67 labelling index of 2%; clear margins).
The patient had been discharged from followup in 2005
with no evidence of recurrence. On representing in 2009,
a CT scan showed evidence of local recurrence with left-
sided pleural lesions and an enlarged left hilar lymph node,
as well a solitary 4.7cm splenic lesion (Figure 1). The
patient was further investigated with Octreotide SPECT and
Gallium 68 whole body PET studies, which showed uptake
in the pleural lesions, no uptake of the splenic lesion, and
normal appearance of the abdominal and pelvic viscera.
However, increased activity was demonstrated in the left
acetabulum,which wasthoughttorepresentbonymetastasis.
An ultrasound guided percutaneous biopsy of the splenic2 HPB Surgery
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Figure 1: CT scan showing a 4.7cm solitary splenic lesion.
lesion diagnosed a low-grade neuroendocrine carcinoma
in keeping with metastasis of the resected lung primary
(chromogranin, cam 52, panCK, MFF116, synaptophysin,
CD56 positive: no necrosis; no mitoses; Ki67 labelling
index<5%). After a multidisciplinary discussion, a funding
application for Lutetium 177 DOTATATE therapy was made.
Prior to the commencement of this therapy, a repeat CT
scan in September 2009 showed a decrease in the size of the
patient’spleuraldeposits,butanincreaseinthespleniclesion
to 5.8cm. In view of the isolated progression of the splenic
lesion, it was decided that Lutetium therapy would be more
eﬀectivefollowingareductioninthetumourloadbyexcision
of the splenic mass. As a result, the patient underwent a
laparoscopic splenectomy in November 2009.
The patient was placed in the right lateral decubitus
position,and4portswereplacedintheleftﬂank.Thecolonic
attachments were divided, and the short gastric vessels were
controlled with the Ligasure vessel sealing system (Covidien,
Valleylab, Boulder, CO, US) to allow isolation of the splenic
hilum (Figure 2(a)). The splenic artery was then dissected
and ligated with a hemostatic clip (Figure 2(b)). Finally, the
splenic hilar vesselswere dissected anddividedusing avascu-
lar linear stapler (Ethicon Endo-Surgery, Inc. Cininnati, OH,
US) (Figure 2(c)). Following complete splenic mobilisation
(Figure 2(d)), the spleen was placed in a leak-proof bag
and exteriorised to the abdominal wall. Histological analysis
of the specimen conﬁrmed a metastatic carcinoid tumour
(chromogranin, cam 5.2, MFF116, synaptophysin, NSE and
CD56 positive; no necrosis; Mitotic count 2 per HPF; Ki67
labellingindex<5%).Thepatientmadeagoodpostoperative
recovery and was discharged on the second postoperative
day.
Since discharge the patient has been commenced on
Lutetium 177 DOTATATE therapy. Prior to commencement,
repeat PET scan in April 2010 showed the formation of
severalliver metastases. The patient’s pleural disease had also
increased whilst her bony acetabular lesion was unchanged
in appearance. The patient has since completed 3 cycles of
Lutetium therapy and her latest Gallium PET scan from
October 2010 shows little disease progression. Clinically, the
patient has no symptoms of carcinoid syndrome and but
suﬀers from chronic pain at the sights of her left pleural
deposits and left acetabularmetastasis. She is currently being
considered for external beam radiotherapy to her left hip.
3.Discussion
Carcinoidtumoursareuncommonneuroendocrinetumours
primarily aﬀecting the gastrointestinal tract and the bron-
chopulmonary tree [6, 7]. They have unpredictable malig-
nant potential with approximately one quarter of bronchial
carcinoids undergoing invasive growth or metastatic spread.
Overall, their slow rate of growth ensures a relatively
good prognosis for bronchial carcinoids with a ﬁve-decade
multicentre study reporting ﬁve-year survival rates of 73.5%
[4].
Splenic metastasis of solid tumours is rare and is most
often seen with extensive multivisceral metastatic disease
from breast, lung, ovarian, gastric, and skin melanoma
primaries [8]. This case presented as local disease recurrence
with a solitary splenic mass on imaging although more sen-
sitive radioactive labelled imaging later identiﬁed probable
metastasis to the left acetabulum. Solitary splenic metastasis
in the absence of multivisceral disease is extremely rare with
Comp´ eret et al. showing only 93 reported cases up to 2007
[9]. Of these only 10 were from lung primaries, with just
1 previous reported case of pulmonary carcinoid metastasis
involving the spleen [4]. As in the current case, this previous
case involved a metachronous metastasis presenting 8 years
after the diagnosis of the lung primary. It is also interesting
to note that in the current case, the metastases arose from a
left-sided primary carcinoid. Splenic metastases have indeed
been found to arise more commonly from the left lung than
the right [10].
In view of the rarity of splenic metastasis, splenic
lesions in the context of known malignant disease present
a diagnostic challenge. It must be assumed that any lesion
in this setting is a metastasis, but it is preferable to obtain
a tissue diagnosis for conﬁrmation as in the case presented.
D e s p i t es o m ec o n c e r n so fh a e m o r r h a g i cr i s kf r o ms u c h
highlyvascularisedtissue,ultrasoundguidedbiopsyhasbeen
showed to be safe with comparable complication rates to
biopsies of other abdominal organs [11].
Splenectomy for metastatic splenic lesions is generally
indicated to prevent further metastatic spread, to improve
the eﬃcacy of adjuvant therapy and, therefore, improve
survival, or to prevent complications such as splenic vein
thrombosis, painful splenomegaly, and splenic rupture. In a
review of13 casesof splenic metastasis from lungcarcinoma,
Ando et al. report that out of6 patients who did not undergo
splenectomy, 4 (67%) went on to have splenic rupture with
associated poor outcomes [12].
Laparoscopic splenectomy (LS) has become the standard
treatment for benign and malignant haematological disor-
ders requiring splenectomy [5]. However, there is a lack of
evidence for the use of LS in the management of isolated
malignant tumours of the spleen, most likely due to the
rarity ofthe condition. The genericbeneﬁts ofa laparoscopic
approach to abdominal pathology apply to splenic surgery
with a reduction in wound morbidity, shorter hospital stayHPB Surgery 3
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Figure 2: Intraoperative images of the performed laparoscopic splenectomy. (a) Ligation of the short gastric arteries. (b) Dissection and
ligation of the splenic artery. (c) Ligation of the splenic hilum using the Ethicon stapler. (d) View of the operative ﬁeld after completion of
splenectomy.
and recovery times, and improved quality of life. The advan-
tage of a laparoscopic approach is particularly beneﬁcial in
cases of malignancy as the associated shorter recovery times
allow an earlier introduction of chemotherapeutic agents.
Makrin et al. report their experience with LS in the
treatment of 28 isolated splenic tumours and advocate its
use in most cases of splenectomy for solid tumours, except
in the case of substantial splenomegaly [13]. All 28 cases
were treated successfully with no postoperative mortality.
However, 4 cases required conversion to an open procedure
to allow removal of an enlarged spleen. In cases where an
enlarged spleen is encountered, a hand-assisted laparoscopic
approach can also be employed to allow easier mobilisation
of the spleen and resection of adjacent organs or tissues
where needed [14].
4.Conclusion
This paper provides a further account of the rare event
of metastatic carcinoid involving the spleen and the ﬁrst
application of a successful laparoscopic resection for its
treatment. This case oﬀersfurther evidencethatlaparoscopic
splenectomy is a safe alternative to open resection in the
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